1-溴-3-氯丁烷 | 56481-42-6

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氯化物
• 中文名称: 1-溴-3-氯丁烷
• 英文名称: 1-bromo-3-chlorobutane
• 英文别名: 1-Brom-3-chlor-butan；3-Chlor-1-brom-butan
• CAS: 56481-42-6
• 化学式: C₄H₈BrCl
• 分子量: 171.465
• InChiKey: ZHTDTJPDPPKLTG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  6
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1-溴-3-氯丁烷 在 potassium hydrosulfide 、 氢氧化钾 作用下， 以 乙醇 、 水 为溶剂， 反应 9.0h， 以63%的产率得到2-methyl-thietane
  参考文献：
  名称：

  Synthesis of 2-alkyl(aryl)thietanes

  摘要：

  Thietane and its 2-substituted derivatives were synthesized. A general preparation procedure for the synthesis of thietanes bearing alkyl and aryl substituents in the (x-position was developed. Using this procedure, 2-substituted thietanes can be obtained from cheap and easily accessible raw materials in three steps. 2-R-Thietanes (where R = H, CH3, C4H9,C5H11,C6H13,C6H5) and the corresponding sulfoxides and sulfones were synthesized and examined. Intermediate and by-products of the synthesis were studied.

  DOI：

  10.1134/s0965544107020089
• 作为产物：
  描述：

  1,3-二溴丁烷 在 五氯化钼 作用下， 以 二氯甲烷 为溶剂， 生成 1-溴-3-氯丁烷
  参考文献：
  名称：

  Halogen interchange in alkyl halides using molybdenum(V) chloride

  摘要：

  DOI：

  10.1021/jo00910a034

文献信息

• Practical and Selective sp ³ C−H Bond Chlorination via Aminium Radicals
  作者：Alastair J. McMillan、Martyna Sieńkowska、Piero Di Lorenzo、Gemma K. Gransbury、Nicholas F. Chilton、Michela Salamone、Alessandro Ruffoni、Massimo Bietti、Daniele Leonori

  DOI：10.1002/anie.202100030

  日期：2021.3.22

  also the fine‐tuning of physicochemical and biological properties of drugs, agrochemicals and polymers. We report here a general and practical photochemical strategy enabling the site‐selective chlorination of sp3 C−H bonds. This process exploits the ability of protonated N‐chloroamines to serve as aminium radical precursors and also radical chlorinating agents. Upon photochemical initiation, an efficient

  将氯原子引入有机分子对于工业化学品的制造、先进合成中间体的精制以及药物、农用化学品和聚合物的物理化学和生物特性的微调至关重要。我们在这里报告了一种通用且实用的光化学策略，能够实现 sp 3 C−H 键的位点选择性氯化。该过程利用了质子化的N-氯胺作为铵自由基前体和自由基氯化剂的能力。在光化学引发后，建立了有效的自由基链传播，由于存在大量兼容的官能团，因此允许多种底物的官能化。通过适当选择铵基，能够协同最大化 H 原子转移过渡态中的极性和空间效应，为自由基 sp 3 C−H 氯化提供了已知的最高选择性。
• Imidazo (1,2-A)-Indeno (1,2-E) pyrazin-4-one derivatives and
  申请人：Rhone-Poulenc Rorer S.A.

  公开号：US05807859A1

  公开（公告）日：1998-09-15

  Pharmaceutical compositions containing, as the active principle, compounds of formula (I): ##STR1## wherein R, R.sub.1 and R.sub.2 are as defined in the description, or salts thereof, the novel compounds of formula (I), and the preparation thereof. The compounds of formula (I) have valuable pharmacological properties and are alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists, this receptor also being known as the quisqualate receptor. Furthermore, the compounds of formula (I) are non-competitive N-methyl-D-aspartate (NDMA) receptor antagonists, and particularly NMDA receptor glycine modulation site ligands.

  含有作为活性原理的化合物的药物组合物，其化学式为(I)：##STR1##其中R、R.sub.1和R.sub.2如描述中所定义，或其盐，化学式(I)的新化合物及其制备方法。化学式(I)的化合物具有有价值的药理特性，是α-氨基-3-羟基-5-甲基-4-异恶唑丙酸（AMPA）受体拮抗剂，该受体也被称为喹氨酸受体。此外，化学式(I)的化合物是非竞争性N-甲基-D-天冬氨酸（NDMA）受体拮抗剂，特别是NMDA受体甘氨酸调节位点配体。
• Naphthyridine derivatives
  申请人：Sumitomo Pharmaceuticals Company, Ltd.

  公开号：US05843957A1

  公开（公告）日：1998-12-01

  Naphthyridine derivative of the formula: ##STR1## wherein Ring A is substituted or unsubstituted pyridine, X is --N(R.sup.2)--CO--(R.sup.2 is H, alkyl, substituted alkyl, etc.), Z is a direct bond, --NH--, C.sub.1 -C.sub.2 alkylene, or --CH.dbd.CH--, Y is alkyl, substituted alkyl, aromatic group or substituted aromatic group, etc., B is alkyl, substituted alkyl, aromatic group or substituted aromatic group, or an acid addition salt thereof, these compounds having acyl-CoA: cholesterol acyl transferase inhibitory activity, and being useful as an agent for prophylaxis or treatment of hyperlipidemia, atherosclerosis, and related diseases thereof.

  Naphthyridine衍生物的化学式为：##STR1## 其中环A是取代或未取代的吡啶，X为--N(R.sup.2)--CO--(R.sup.2为H、烷基、取代烷基等)，Z为直接键、--NH--、C.sub.1 -C.sub.2烷基或--CH.dbd.CH--，Y为烷基、取代烷基、芳香族基或取代芳香族基等，B为烷基、取代烷基、芳香族基或取代芳香族基，或其酸盐加合物，这些化合物具有酰基辅酶A：胆固醇酰基转移酶抑制活性，并可用作预防或治疗高脂血症、动脉粥样硬化及相关疾病的药物。
• Compound having tgfß inhibitory activity and medicinal composition containing the same
  申请人：Shimizu Kiyoshi

  公开号：US20060111375A1

  公开（公告）日：2006-05-25

  The present invention provides compounds represented by formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein X represents CH or N; Z represents —O—, —NH— or —C(═O)—; R and R′ represent a hydrogen atom, hydroxyl, a halogen atom, optionally substituted alkyl, optionally substituted alkenyl optionally substituted alkoxy, amino, aminocarbonyl, or an optionally substituted heterocyclic group; and A represents an optionally substituted specific carbocyclic or heterocyclic group. The compounds according to the present invention have excellent TGFβ inhibitory activity.

  本发明提供了以下公式（I）所表示的化合物及其药学上可接受的盐和溶剂： 其中，X代表CH或N；Z代表-O-，-NH-或-C（=O）-；R和R'代表氢原子，羟基，卤原子，可选择取代的烷基，可选择取代的烯基，可选择取代的烷氧基，氨基，氨基甲酰基或可选择取代的杂环基；A代表可选择取代的特定环烷基或杂环基。本发明的化合物具有出色的TGFβ抑制活性。
• COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：Shimizu Kiyoshi

  公开号：US20090312313A1

  公开（公告）日：2009-12-17

  The present invention provides compounds represented by formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein X represents CH or N; Z represents —O—, —NH— or —C(═O)—; R and R′ represent a hydrogen atom, hydroxyl, a halogen atom, optionally substituted alkyl, optionally substituted alkenyl optionally substituted alkoxy, amino, aminocarbonyl, or an optionally substituted heterocyclic group; and A represents an optionally substituted specific carbocyclic or heterocyclic group. The compounds according to the present invention have excellent TGFβ inhibitory activity.

  本发明提供了由式(I)表示的化合物及其药学上可接受的盐和溶剂： 其中，X代表CH或N；Z代表—O—、—NH—或—C(═O)—；R和R′代表氢原子、羟基、卤素原子、可选取代的烷基、可选取代的烯基、可选取代的烷氧基、氨基、氨基甲酰基或可选取代的杂环基；A代表可选取代的特定环烷基或杂环基。本发明的化合物具有优异的TGFβ抑制活性。